H1N1 News and Research

RSS

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.

HTDS finalizes contract details with Indian pharmaceutical company

Hard to Treat Diseases' (HTDS; http://www.htdsmedical.com/) operating subsidiary Mellow Hope finalized contract details with one of the largest manufacturer of intravenous medication in India.

1 Dec 2009

Members of priority groups to receive H1N1 vaccines from Department of Health

The Department of Health reminded Pennsylvanians they can begin making appointments today to be vaccinated against the H1N1 flu virus.

1 Dec 2009

Research shows many factors can impact people's decisions on getting vaccinated

Just because a vaccine is available doesn't mean people will choose to be inoculated, according to new UofT research published amid widespread public confusion around the merit of H1N1 flu shots.

1 Dec 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

27 Nov 2009

Majority of Canadians want to keep their commitment to reduce child deaths around the world

GTA parents and children gathered at an African-style clinic in downtown Toronto today, where World Vision released a poll that showed most Canadians (84%) think it's great that a lot of focus is placed on immunizing Canadian children against the H1N1 flu and other diseases. They (79%) want to see just as much focus on immunizing children in poor countries.

27 Nov 2009

ALDA Pharmaceuticals and Shoppers Drug Mart sign distribution agreement

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") announces that it has entered into an agreement with Shoppers Drug Mart Corporation ("Shoppers") that will make the Company's T36® Antiseptic Hand Sanitizer available in over 1,170 Shoppers Drug Mart and Pharmaprix stores across Canada.

26 Nov 2009

Experts say vitamin D assists body's immune system to fight against H1N1

The world's leading vitamin D experts say that raising your levels of "the sunshine vitamin" this winter might be the best way to help your body naturally raise its resistance to all forms of the flu virus - including the H1N1 swine flu virus.

26 Nov 2009

Local parents and pre-school children join Tom Cochrane to launch World Vision's Five for 5 campaign

The World Vision clinic, modeled after a typical African community clinic, will stand in sharp contrast to the now-common sight of parents and children receiving the care they need at Canadian H1N1 flu shot clinics.

26 Nov 2009

Lethality of H1N1 virus has dropped from its peak of 3.7, shows new data

Biotech firm Replikins Ltd., which has analyzed the H1N1 virus' genomic data from the 1918 pandemic through the prediction, outbreak, and progress of the current H1N1 pandemic, today issued its latest biochemical analysis of the virus.

25 Nov 2009

WHO investigates cases of H1N1 drug resistance in U.S., Britain

The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.

25 Nov 2009

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

25 Nov 2009

Pennsylvanians at-risk for H1N1 flu receive H1N1 vaccination

Governor Edward G. Rendell today announced that 100,000 Pennsylvanians at-risk for the H1N1 flu were vaccinated during the weekend at public health clinics held by the Department of Health and local health departments.

25 Nov 2009

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed.

25 Nov 2009

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProParaflu+(TM) assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections.

25 Nov 2009

Africa region leaders meet to discuss H1N1 procurement, distribution

Representatives of African countries are meeting in Abuja this week to discuss the procurement and distribution of the H1N1 (swine flu) vaccine, the Daily Trust/allAfrica.com reports (Rabiu, 11/23).

24 Nov 2009

Fourth-quarter and year-end fiscal 2009 results announced by Allied Healthcare International

Allied Healthcare International Inc., a leading provider of flexible healthcare staffing services in the United Kingdom, has issued financial results for its fiscal 2009 fourth quarter and year-end.

24 Nov 2009

Fourth-quarter and full year fiscal 2009 results announced by Hillenbrand

Hillenbrand reported net revenues of $153.1 million for the fourth quarter of 2009, which ended Sept. 30, 2009, a $5.7 million (3.6 percent) decline from the same period in fiscal 2008. The company posted net income of $22.6 million, a $3.4 million (17.7 percent) increase from last year.

24 Nov 2009

Iowa State University's researcher develops and ships H1N1 vaccine for swine producers

The only swine vaccine available for the H1N1 virus has been sent to vaccinate a swine herd infected with the virus. The vaccination marks the first time vaccine has been sent to a swine herd diagnosed with the pandemic flu.

24 Nov 2009